HLS Therapeutics (TSE:HLS) Announces Earnings Results

HLS Therapeutics (TSE:HLS) released its quarterly earnings data on Wednesday. The company reported C($0.03) EPS for the quarter, RTT News reports. The company had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%.During the same quarter in the previous year, the company posted ($0.09) EPS.

Here are the key takeaways from HLS Therapeutics’ conference call:

• Cardiovascular portfolio growth accelerated: Q2 net sales rose 25% year over year, led by 18% Vascepa growth and NILEMDO’s first full quarter of sales exceeding $300,000.
• NILEMDO access and uptake are progressing ahead of plan. Nearly 1,200 patients had started treatment by the end of Q2, private-payer coverage now reaches approximately 80% of privately insured Canadians, and public reimbursement negotiations are expected to begin later this year.
• Additional growth catalysts are approaching: NEXLIZET remains on track for a Health Canada decision by year-end and a potential launch in the first half of 2027, while management expects NILEMDO momentum to strengthen in the second half of 2026.
• CLOZARIL trends were mixed but improving in Canada. The Canadian branded patient base grew for five consecutive months and Q2 sales declined only 1%, while U.S. sales fell to $3.0 million; management expects relatively flat U.S. year-over-year comparisons in the second half.
• Management reaffirmed 2026 guidance of CAD 56–60 million in revenue and CAD 18.5–21 million in Adjusted EBITDA, citing expected second-half margin expansion, lower interest costs, debt reduction, and an active share buyback program.

HLS Therapeutics Stock Down 2.8%

HLS Therapeutics stock opened at C$3.87 on Friday. The stock has a market capitalization of C$121.03 million, a PE ratio of -12.09 and a beta of -0.18. HLS Therapeutics has a 12 month low of C$3.77 and a 12 month high of C$5.77. The business has a 50 day simple moving average of C$4.23 and a 200-day simple moving average of C$4.41. The company has a debt-to-equity ratio of 75.00, a current ratio of 1.00 and a quick ratio of 1.01.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group raised shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of C$6.00.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.